Literature DB >> 7059993

Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential.

B F Sloane, K V Honn, J G Sadler, W A Turner, J J Kimpson, J D Taylor.   

Abstract

In solid s.c. tumors of a variant of the murine B16 melanoma with high metastatic potential (B16F10), there was a 2- to 7-fold elevation of lysosomal cathepsin B activity when compared to the B16F1 variant with low metastatic potential. The highest activities (based on either protein or DNA) of cathepsin B were found in tumors of less than 1 g. When B16F1 and B16F10 melanoma variants were grown in tissue culture, the metastatic differential in cathepsin B activity was lost as the cells were subcultured. However, this differential in cathepsin B activity could be restored by reestablishing the cultured cells as s.c. tumors. The activities of four other lysosomal enzymes (cathepsin D, beta-N-acetylglucosaminidase, beta-glucuronidase, and acid phosphatase) showed little evidence of a positive correlation with the metastatic potential of the B16 melanoma variants. Eighty to 90% of cathepsin B activity has been localized to a fraction containing viable tumor cells which was isolated by centrifugal elutriation. In contrast, only 50% of cathepsin D activity was in the viable tumor cell fraction, and from 30 to 70% of beta-N-acetylglucosaminidase, beta-glucuronidase, and acid phosphatase. Elevated levels of cathepsin B in the high metastatic B16F10 variant are consistent with the idea that cathepsin B may play a direct or a regulatory role in tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Modification of the metastatic potential of tumor cells by drugs.

Authors:  K Takenaga
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

Review 2.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

3.  Isolation of a cDNA clone for the human lysosomal proteinase cathepsin B.

Authors:  D Fong; D H Calhoun; W T Hsieh; B Lee; R D Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells.

Authors:  S Aznavoorian; M L Stracke; H Krutzsch; E Schiffmann; L A Liotta
Journal:  J Cell Biol       Date:  1990-04       Impact factor: 10.539

5.  Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene.

Authors:  C G Huh; K Håkansson; C M Nathanson; U P Thorgeirsson; N Jonsson; A Grubb; M Abrahamson; S Karlsson
Journal:  Mol Pathol       Date:  1999-12

6.  Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13.

Authors:  H Fujii; M Nakajima; I Saiki; J Yoneda; I Azuma; T Tsuruo
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

7.  Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours.

Authors:  T Kageshita; A Yoshii; T Kimura; K Maruo; T Ono; M Himeno; Y Nishimura
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 8.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

9.  Brain surface invasion and metastasis of murine malignant melanoma variants.

Authors:  G L Nicolson; T Kawaguchi; M Kawaguchi; C Van Pelt
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

10.  Purification and partial characterization of a tumour-metastasis-associated high-Mr glycoprotein from rat 13762NF mammary adenocarcinoma cells.

Authors:  P A Steck; S M North; G L Nicolson
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.